| Next 10 |
Ad
ANIK News and Press Anika Therapeutics Inc.
-
Anika Therapeutics, Inc. (ANIK) Q3 2022 Results Conference Call November 08, 2022 05:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mi...
-
Anika Therapeutics press release ( NASDAQ: ANIK ): Q3 Non-GAAP EPS of -$0.05 beats by $0.18 . Revenue of $40.3M (+1.9% Y/Y) beats by $2.71M . For further details see: Anika Therapeutics Non-GAAP EPS of -$0.05 beats by $0.18, revenue of $40.3M beats by $2....
-
Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone Pivotal Phase III Clinical Trial for Hyalofast®, HA-Based, Single-...
-
Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks Study Builds on Prior Phase III Study Data that Demonstrated Superiority over Plac...
-
BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tue...
-
BEDFORD, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the limited market release and the first surgeries performed using the X-Twist Fixation System. Chr...
-
Anika Therapeutics, Inc. (ANIK) Q2 2022 Earnings Conference Call August 03, 2022, 05:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michae...
-
The following slide deck was published by Anika Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Anika Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
-
Anika Therapeutics press release ( NASDAQ: ANIK ): Q2 Non-GAAP EPS of -$0.12 beats by $0.09 . Revenue of $39.7M (+4.2% Y/Y) beats by $1.85M . The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance ran...
-
Second quarter revenue growth up 4% X-Twist ™ 510(k) clearance received; Limited market release on schedule for 2H 2022 BEDFORD, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in earl...
Stock Information
Anika Therapeutics Inc. Company Name:
ANIK Stock Symbol:
NASDAQ Market:
Anika Therapeutics Inc. Website:
Get ANIK Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
